Vaccinex, Inc.

FOR IMMEDIATE RELEASE

VACCINEX, INC. ANNOUNCES NEWLY DESIGNED WEB SITE

Rochester, N.Y. January 29, 2002 Vaccinex, Inc., announced today the launch of its redesigned website, www.vaccinex.com. The revamped site coincides with dramatic expansion taking place at Vaccinex and the company's move to its new world headquarters, slated for March 2002. Developed in collaboration with Dixon-Schwabl Advertising, Inc., a Rochester-based marketing firm, the redesigned site has a variety of new features that will facilitate navigation and enhance overall visitor experience, with:

· User-friendly navigation and design, including a detailed glossary.

· An animated presentation, illustrating Vaccinex' functional gene discovery technology.

· Regularly up-dated press releases, documenting Vaccinex' commercial and scientific achievements.

"There has been a surge in the level of interest in Vaccinex over the past 4 to 6 months. The redesigned site will assist interested parties, which include investors, investigators, and members of the media, in obtaining comprehensive coverage of Vaccinex' commercial and scientific advances", said J. Jeffrey Goater, Business Development Associate at Vaccinex.

Vaccinex, Inc., headquartered in Rochester, New York, is a privately owned biopharmaceutical company engaged in the development of therapeutic monoclonal antibodies and vaccines to treat cancer and other diseases. Founded in 1997, the company is at the forefront of the genomics revolution, leveraging powerful proprietary research tools to identify target genes involved in the development of a wide variety of diseases, and then using this newly acquired knowledge to develop effective therapies. Please visit the company's website at www.vaccinex.com.

Back to News Archive


About Us Executive Team Board of Directors Scientific/ Clinical Advisors Business Strategy Collabora- tions Antibody Technology Overview Membrane Antibody Expression and Selection Secreted IgG Antibody Selection Antibody Animation Development Strategy Development Pipeline


	FOR IMMEDIATE RELEASE VACCINEX, INC. ANNOUNCES NEWLY DESIGNED WEB SITE Rochester, N.Y. January 29, 2002 Vaccinex, Inc., announced today the launch of its redesigned website, www.vaccinex.com. The revamped site coincides with dramatic expansion taking place at Vaccinex and the company's move to its new world headquarters, slated for March 2002. Developed in collaboration with Dixon-Schwabl Advertising, Inc., a Rochester-based marketing firm, the redesigned site has a variety of new features that will facilitate navigation and enhance overall visitor experience, with: · User-friendly navigation and design, including a detailed glossary. · An animated presentation, illustrating Vaccinex' functional gene discovery technology. · Regularly up-dated press releases, documenting Vaccinex' commercial and scientific achievements. "There has been a surge in the level of interest in Vaccinex over the past 4 to 6 months. The redesigned site will assist interested parties, which include investors, investigators, and members of the media, in obtaining comprehensive coverage of Vaccinex' commercial and scientific advances", said J. Jeffrey Goater, Business Development Associate at Vaccinex. Vaccinex, Inc., headquartered in Rochester, New York, is a privately owned biopharmaceutical company engaged in the development of therapeutic monoclonal antibodies and vaccines to treat cancer and other diseases. Founded in 1997, the company is at the forefront of the genomics revolution, leveraging powerful proprietary research tools to identify target genes involved in the development of a wide variety of diseases, and then using this newly acquired knowledge to develop effective therapies. Please visit the company's website at www.vaccinex.com. Back to News Archive Copyright © 2008 Vaccinex, Inc.